Det er interessant at Genmab får Zalutumumab i Lancet-oncology.
-
Det er interessant at Genmab får Zalutumumab i Lancet-oncology.
Det kan så både tolkes positivt og negativt:Positivt: Vi har god effekt af Zalu, men har inkluderet for få patienter til at vise signifikans, da best supportive care var bedre end antaget (pga Methotrexat) - Så har Peter Aabo fat i den lange ende!
Negativt: Vi kunne ikke vise signifikant bedre effekt af Zalu end af Methotrexat. - Så får vi alle en lang næse.
Det rejser så spørgsmålet om Erbitux er bedre end methotrexat...
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind